Criterium

• NCT05230810

  Phase 1/2, Active, not recruiting, 40 people, 9 Feb 2022

• DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)

  Phase 2, Active, not recruiting, 70 people, 28 Sept 2020

• NCT04169347

  Phase 2, Status unknown, 27 people, 19 Nov 2019

• NCT03054363

  Collaborator, Phase 1/2, Completed, 42 people, 15 Feb 2017

• NCT01789242

  Phase 1, Completed, 32 people, 12 Feb 2013

• NCT01660750

  Phase 1, Completed, 29 people, 9 Aug 2012

• NCT01464034

  Phase 1/2, Terminated, 136 people, 3 Nov 2011

Sources: clinicaltrials.gov